← All trials
NCT04668950
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Sep 30, 2021
- First posted
- Dec 16, 2020
- Last posted
- Dec 24, 2020
- Enrollment
- 1100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Washington University in St. LouisLead sponsor
- Washington University in St. LouisReponsible party - principal investigator
- Cures Within ReachCollaborator
- Covid-19 Early Treatment FundCollaborator
- McGill UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.